Cover Image
市場調查報告書

Ocular Therapeutix, Inc.的產品平台分析

Ocular Therapeutix, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293961
出版日期 內容資訊 英文 30 Pages
訂單完成後即時交付
價格
Back to Top
Ocular Therapeutix, Inc.的產品平台分析 Ocular Therapeutix, Inc. - Product Pipeline Review - 2015
出版日期: 2015年11月18日 內容資訊: 英文 30 Pages
簡介

Ocular Therapeutix, Inc.是總公司設立於美國的醫療設備企業,利用包含聚乙二醇的水凝膠技術開發治療眼睛疾病用產品。產品有淚管塞及眼球後區之藥劑注射器、外科手術時所用的眼球用給藥器等。

本報告提供Ocular Therapeutix, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃相關資訊等。

目錄

Ocular Therapeutix, Inc.的基本資料

  • Ocular Therapeutix, Inc.概要
  • 主要資訊
  • 企業資料

Ocular Therapeutix, Inc.:R&D概要

  • 主要的治療範圍

Ocular Therapeutix, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Ocular Therapeutix, Inc.:開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Ocular Therapeutix, Inc.:藥物簡介

  • dexamethasone acetate SR
  • travoprost SR
  • moxifloxacin hydrochloride SR
  • Protein to Inhibit VEGF for Ophthalmology

Ocular Therapeutix, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Ocular Therapeutix, Inc.:最新的開發平台資訊

Ocular Therapeutix, Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07777CDB

Summary

Global Markets Direct's, 'Ocular Therapeutix, Inc. - Product Pipeline Review - 2015', provides an overview of the Ocular Therapeutix, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ocular Therapeutix, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Ocular Therapeutix, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ocular Therapeutix, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ocular Therapeutix, Inc.'s pipeline products

Reasons to buy

  • Evaluate Ocular Therapeutix, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ocular Therapeutix, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ocular Therapeutix, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ocular Therapeutix, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ocular Therapeutix, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ocular Therapeutix, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ocular Therapeutix, Inc. Snapshot
    • Ocular Therapeutix, Inc. Overview
    • Key Information
    • Key Facts
  • Ocular Therapeutix, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Ocular Therapeutix, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Ocular Therapeutix, Inc. - Pipeline Products Glance
    • Ocular Therapeutix, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Ocular Therapeutix, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Ocular Therapeutix, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Ocular Therapeutix, Inc. - Drug Profiles
    • dexamethasone acetate SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • travoprost SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • moxifloxacin hydrochloride SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit VEGF for Wet Macular Degeneration
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Protein to Inhibit VEGF for Wet Age Related Macular Degeneration
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ocular Therapeutix, Inc. - Pipeline Analysis
    • Ocular Therapeutix, Inc. - Pipeline Products by Target
    • Ocular Therapeutix, Inc. - Pipeline Products by Route of Administration
    • Ocular Therapeutix, Inc. - Pipeline Products by Molecule Type
    • Ocular Therapeutix, Inc. - Pipeline Products by Mechanism of Action
  • Ocular Therapeutix, Inc. - Recent Pipeline Updates
  • Ocular Therapeutix, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ocular Therapeutix, Inc., Key Information
  • Ocular Therapeutix, Inc., Key Facts
  • Ocular Therapeutix, Inc. - Pipeline by Indication, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Stage of Development, 2015
  • Ocular Therapeutix, Inc. - Monotherapy Products in Pipeline, 2015
  • Ocular Therapeutix, Inc. - Pre-Registration, 2015
  • Ocular Therapeutix, Inc. - Phase III, 2015
  • Ocular Therapeutix, Inc. - Phase II, 2015
  • Ocular Therapeutix, Inc. - Phase I, 2015
  • Ocular Therapeutix, Inc. - Preclinical, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Target, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Route of Administration, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Molecule Type, 2015
  • Ocular Therapeutix, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Ocular Therapeutix, Inc. - Recent Pipeline Updates, 2015
  • Ocular Therapeutix, Inc., Other Locations

List of Figures

  • Ocular Therapeutix, Inc. - Pipeline by Top 10 Indication, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Stage of Development, 2015
  • Ocular Therapeutix, Inc. - Monotherapy Products in Pipeline, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Top 10 Target, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Ocular Therapeutix, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top